Skip to main content
. 2014 Jun;184(6):1831–1842. doi: 10.1016/j.ajpath.2014.03.003

Figure 4.

Figure 4

Expression of myostatin and activin receptor type IIB in VEH- and ActRIIB-treated mice. A: Western blot analysis shows the relative expression of myostatin and the activin type IIB receptor in the quadriceps and gastrocnemius muscles of VEH- and ActRIIB-treated WT and R69C mice at 6 MOL. GAPDH staining is used as a basis for loading and quantification studies. The numbers under each set of two lanes refer to individual mice from the study. B: Quantification of myostatin and activin type IIB receptor expression in the quadriceps and gastrocnemius muscles of VEH- and ActRIIB-treated WT and R69C mice. Expression is normalized to the GAPDH expression for each lane. These values were obtained from gels in which the WT and R69C samples were run in parallel on the same gels and immunoblotted on the same membranes. Data are expressed as means ± SEM. ∗P < 0.05. ActRIIB, ActRIIB-mFC; G, gastrocnemius; Q, quadriceps; R69C, Mtm1 p.R69C; VEH, vehicle.